Medulloblastoma Clinical Trials

14 recruiting

Frequently Asked Questions

Common questions about Medulloblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 1Phase 2

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

GlioblastomaGliomaMedulloblastoma+1 more
National Cancer Institute (NCI)146 enrolled1 locationNCT06161519
Recruiting
Not Applicable

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

MedulloblastomaEpendymomaEpendymoma of Brain+3 more
University of California, San Francisco74 enrolled8 locationsNCT05057702
Recruiting
Phase 1

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

PineoblastomaEmbryonal Tumor With Multilayered RosettesEpendymoma+3 more
Children's National Research Institute12 enrolled1 locationNCT06193759
Recruiting
Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

NeuroblastomaPineoblastomaAtypical Teratoid/Rhabdoid Tumor+11 more
C17 Council15 enrolled12 locationsNCT06942039
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 2

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Medulloblastoma
St. Jude Children's Research Hospital130 enrolled10 locationsNCT05535166
Recruiting
Phase 1

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Pediatric Brain TumorPineoblastomaMedulloblastoma+7 more
Stanford University18 enrolled1 locationNCT07087002
Recruiting
Phase 3

Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour

Cognitive ImpairmentMedulloblastoma, Childhood
Donald Mabbott140 enrolled20 locationsNCT05230758
Recruiting
Phase 1

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Central Nervous System NeoplasmsGlioblastomaHigh Grade Glioma+4 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT05835687
Recruiting
Phase 1

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

GlioblastomaPrimary Brain TumorMedulloblastoma+1 more
Theodore S. Johnson37 enrolled1 locationNCT05106296
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting
Phase 1

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Germ Cell TumorChoroid Plexus CarcinomaCentral Nervous System Tumor+8 more
Seattle Children's Hospital90 enrolled1 locationNCT04185038
Recruiting
Phase 4

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

ParagangliomaMeningiomaEsthesioneuroblastoma+4 more
Weill Medical College of Cornell University200 enrolled1 locationNCT04081701
Recruiting
Phase 1Phase 2

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Solid TumorsEwing SarcomaNeuroblastoma+3 more
Valent Technologies, LLC20 enrolled8 locationsNCT04337177
Recruiting
Phase 2

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

High Grade GliomaDiffuse Intrinsic Pontine GliomaRecurrent Medulloblastoma
Nationwide Children's Hospital120 enrolled12 locationsNCT05096481
Recruiting
Phase 1

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

High Grade GliomaDiffuse Intrinsic Pontine GliomaMedulloblastoma+1 more
Emory University18 enrolled2 locationsNCT06624371
Recruiting

Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

GliomaBrain TumorsMedulloblastoma+1 more
Tata Memorial Centre200 enrolled1 locationNCT06779487
Recruiting
Phase 1

GD2-CAR T Cells for Pediatric Brain Tumours

Brain Tumor AdultHigh Grade GliomaDiffuse Intrinsic Pontine Glioma+4 more
Bambino Gesù Hospital and Research Institute54 enrolled1 locationNCT05298995
Recruiting
Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+6 more
Fundación de investigación HM25 enrolled1 locationNCT06607692